



MSD Pipeline

November 1, 2017

Lead-in Language

- The chart below reflects the Company's research pipeline as of **November 1, 2017**. Candidates shown in Phase 3 include specific products and the date such candidate entered into Phase 3 development. Candidates shown in Phase 2 include the most advanced compound with a specific mechanism or, if listed compounds have the same mechanism, they are each currently intended for commercialization in a given therapeutic area. Small molecules and biologics are given MK-number designations and vaccine candidates are given V-number designations. Except as otherwise noted, candidates in Phase 1, additional indications in the same therapeutic area (other than with respect to *Oncology*) and additional claims, line extensions or formulations for in-line products are not shown.

MSD Pipeline as of November 1, 2017

Phase 2	Phase 2	Phase 3	Phase 3	Phase 3
Asthma MK-1029	Diabetes mellitus MK-8521	Alzheimer's disease verubecestat MK-8931	Cancer Breast Colorectal Esophageal Gastric (EU) Hepatocellular Head and neck (EU) ▶ Nasopharyngeal Renal Small Cell Lung KEYTRUDA® MK-3475	HABP/VABP ³ bacterial pneumonia SIVEXTRO® MK-1986
Cancer PMBCL² Advanced solid tumors Ovarian Prostate KEYTRUDA® MK-3475	Pneumoconjugate vaccine V114	Bacterial infection relebactam+imipenem/cilastatin MK-7655A	Cancer Pancreatic Prostate LYNPARZA® MK-7339¹	HIV doravirine MK-1439 HIV doravirine/lamivudine/tenofovir disoproxil fumarate MK-1439A
Cough, including cough w/ IPF ⁴ MK-7264	Schizophrenia MK-8189	Cancer Thyroid Selumetinib MK-5618¹	HABP/VABP ³ bacterial pneumonia ZERBAXA® MK-7625A	Heart failure vericiguat MK-1242¹
▶ Moved forward since last pipeline update.		Ebola vaccine V920	Herpes zoster inactivated VZV vaccine V212	

1. Being developed in a collaboration.
2. Primary Mediastinal Large B-Cell Lymphoma
3. HABP - Hospital-acquired bacterial pneumonia/ VABP - ventilator-associated bacterial pneumonia
4. Idiopathic Pulmonary Fibrosis

MSD Pipeline as of November 1, 2017

New Molecular Entities Under Review	New Molecular Entities Under Review	New Molecular Entities Approvals ¹	New Molecular Entities Approvals ¹
MK-8228 CMV prophylaxis in transplant patients letermovir (US/EU)	MK-8835A ertugliflozin+sitagliptin Diabetes mellitus (EU/US) ⁴	BRIDION® MK-8616 Neuromuscular blockade reversal (US)	VAXELIS™ V419 Pediatric hexavalent combination vaccine (EU) ²
MK-0431J⁴ Diabetes mellitus sitagliptin+ipragliflozin (Japan)	MK-8835B ertugliflozin+metformin Diabetes mellitus (EU/US) ⁴	LUSDUNA® MK-1293 Diabetes mellitus (EU/US) ^{3,4}	ZEPATIER® MK-5172A Hepatitis C (US/EU)
MK-8835 ertugliflozin Diabetes mellitus (EU/US) ⁴	V419 Pediatric hexavalent combination vaccine (US) ²	ZINPLAVA™ MK-6072 Clostridium difficile infection recurrence (US/EU)	

► Moved forward since last pipeline update.

1. Approvals obtained within the last 24 months.
2. V419 is an investigational pediatric hexavalent combination vaccine, DTaP5-IPV-Hib-HepB, that is being developed and, if approved, will be commercialized through a partnership between MSD and Sanofi. In November 2015, the FDA issued a CRL with respect to V419. Both companies are reviewing the CRL and plan to have further communication with the FDA.
3. Received tentative approval from the FDA in July 2017. Final approval remains subject to automatic 30-month stay that began in September 2016.
4. Being developed in a collaboration

MSD Pipeline as of November 1, 2017

Certain
Supplemental
Filings
Under Review

LYNPARZA®
MK-7339¹
2nd Line Metastatic
Breast Cancer
(US)

▶ Moved forward since last pipeline update.

1. Being developed in a collaboration.

MSD Pipeline as of November 1, 2017

Certain Supplemental Approvals ¹	Certain Supplemental Approvals ¹	Certain Supplemental Approvals ¹	Certain Supplemental Approvals ¹	Certain Supplemental Approvals ¹
<p>KEYTRUDA® MK-3475 Previously treated microsatellite instability-high cancer (US)</p>	<p>▶ KEYTRUDA® MK-3475 2nd line metastatic bladder cancer (US/EU)</p>	<p>KEYTRUDA® MK-3475 2nd line non-small cell lung cancer (EU)</p>	<p>EMEND® MK-0517 CINV² in adults receiving moderately emetogenic chemotherapy (MEC) (US)</p>	<p>GARDASIL® 9 V503 2-dose vaccination regimen for use in girls and boys 9-14 years of age (US)</p>
<p>▶ KEYTRUDA® MK-3475 1st line cisplatin-ineligible bladder cancer (US/EU)</p>	<p>KEYTRUDA® MK-3475 Combination with carboplatin and pemetrexed in 1st Line non-squamous non-small cell lung cancer (US)</p>	<p>GARDASIL® 9 V503 Expanded age indication for males for prevention of anal cancers and genital warts caused by nine HPV types (US)</p>	<p>KEYTRUDA® MK-3475 3rd line head and neck cancer (US)</p>	<p>KEYTRUDA® MK-3475 Relapsed or refractory classical Hodgkin Lymphoma (US/EU)</p>
<p>ISENTRESS® Once-daily dosing option in combination with other antiretroviral agents for HIV-1 infection (ISENTRESS HD®) (US/EU)</p>	<p>EMEND® MK-0869 Pediatric indication for CINV² (EU)</p>	<p>KEYTRUDA® MK-3475 1st line melanoma (US)</p>	<p>KEYTRUDA® MK-3475 1st line non-small cell lung cancer (US/EU)</p>	<p>▶ KEYTRUDA® MK-3475 3rd line gastric cancer (US)</p>
<p>▶ LYNPARZA® MK-7339³ New Tablet Formulation and Broader Approval for Ovarian Cancer (US)</p>	<p>▶ Moved forward since last pipeline update.</p>			

1. Approvals obtained within the last 24 months.
2. Chemotherapy-induced nausea and vomiting
3. Being developed in a collaboration.

Forward-Looking Statement

This presentation includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of MSD’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; MSD’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of MSD’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

MSD undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in MSD’s 2016 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).

No Duty to Update

The information contained in the presentation set forth below was current as of November 1, 2017. While this presentation remains on the company's website the company assumes no duty to update the information to reflect subsequent developments. Consequently, the company will not update the information contained in the presentation and investors should not rely upon the information as current or accurate after November 1, 2017.

The chart reflects the MSD research pipeline as of November 1, 2017.

Candidates shown in Phase III include specific products. Candidates shown in Phase II include the most advanced compound with a specific mechanism in a given therapeutic area. Phase I candidates are not shown.